Tumores da córtex da supra-renal: o uso do p53 na diferenciação entre carcinomas e adenomas

A marcacao imunohistoquimica da proteina p53 foi estudada em tumores da adrenal conservados em formol ou em blocos de parafina, pelo metodo da avidina-biotina-peroxidase com recuperacao antigenica. Foram estudados 24 carcinomas e 26 adenomas com o objetivo de verificar se o marcador mostrava capacidade de distincao entre eles. Em 62,5% dos carcinomas a marcacao foi positiva enquanto que nos adenomas foi de 15,4%, diferenca essa estatisticamente significante (p=0,0003). A sensibilidade, especificidade e valor preditivo positivo desse marcador para o diagnostico do câncer foram, respectivamente: 83,3%, 71,8% e 62,5%. Nao houve relacao entre o indice de marcacao e outros parâmetros clinicos, como peso do tumor, estadio local, recidiva e metastases. Os autores concluem que o marcador e util no diagnostico diferencial de massas da adrenal, mas nao tem relacao com a agressividade biologica da neoplasia maligna.

[1]  M. Merino,et al.  Adrenocortical neoplasms: role of prognostic markers MIB-1, P53, and RB. , 1997, The American journal of surgical pathology.

[2]  S. Nilsson,et al.  Biological characteristics of adrenocortical carcinoma: a study of p53, IGF, EGF-r, Ki-67 and PCNA in 17 adrenocortical carcinomas. , 1997, Anticancer research.

[3]  J. Hermans,et al.  Expression of p53 in adrenocortical tumours: clinicopathological correlations , 1997, The Journal of pathology.

[4]  T. Shuin,et al.  Bilateral adrenocortical carcinoma showing loss of heterozygosity at the p53 and RB gene loci. , 1996, Cancer genetics and cytogenetics.

[5]  Y. Fradet,et al.  Prevalence and Clinical Significance of Her-2/neu, p53 and Rb Expression in Primary Superficial Bladder Cancer , 1996 .

[6]  D. Malkin,et al.  Immunohistochemical detection of p53 in Wilms' tumors correlates with unfavorable outcome. , 1996, The American journal of pathology.

[7]  G. Hommel,et al.  The relationship of p53 expression to the prognosis of 418 patients with gastric carcinoma , 1995, Cancer.

[8]  C. Hensel,et al.  Novel germline mutation of the p53 tumor suppressor gene in a child with incidentally discovered adrenal cortical carcinoma. , 1994, The American journal of pediatric hematology/oncology.

[9]  R. Cote,et al.  Strategies for improving the immunohistochemical staining of various intranuclear prognostic markers in formalin-paraffin sections: androgen receptor, estrogen receptor, progesterone receptor, p53 protein, proliferating cell nuclear antigen, and Ki-67 antigen revealed by antigen retrieval techniques , 1994, Human pathology.

[10]  G. Chrousos,et al.  p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies. , 1994, The Journal of clinical endocrinology and metabolism.

[11]  T. Koyanagi,et al.  Clinical experience of incidentally discovered adrenal tumor with particular reference to cortical function. , 1993, The Journal of urology.

[12]  L. Medeiros,et al.  Pathologic Features of Prognostic Significance in Adrenocortical Carcinoma , 1989, The American journal of surgical pathology.

[13]  F. Klein,et al.  Flow cytometric determinations of ploidy and proliferation patterns of adrenal neoplasms: an adjunct to histological classification. , 1985, The Journal of urology.

[14]  H. Slooten,et al.  Morphologic characteristics of benign and malignant adrenocortical tumors , 1985, Cancer.

[15]  P. Copeland The Incidentally Discovered Adrenal Mass , 1984, Annals of internal medicine.

[16]  S. Hsu,et al.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. , 1981, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.